The GFPT2 Knockout Raji Polyclonal Cells represent a polyclonal population of Raji B lymphocytes engineered via CRISPR/Cas9-mediated disruption of the GFPT2 gene, establishing a loss-of-function model system for investigating hexosamine biosynthesis. This polyclonal knockout cell product provides a genetically tractable platform to interrogate the role of GFPT2 in glycosylation-dependent signaling without clonal selection artifacts, enabling robust functional studies in a biologically relevant immune cell context.
Raji cells are a lymphoblastoid B lymphocyte line derived from a Burkitt lymphoma patient, characterized by Epstein-Barr virus positivity and a mutant p53 background. This cell line maintains a type III latency program, expressing the full repertoire of EBV latent genes, and is widely employed as a model for B-cell malignancies and EBV-associated lymphomagenesis. The p53 deficiency further recapitulates common genetic lesions observed in aggressive lymphomas, making Raji a physiologically pertinent host for metabolic and oncogenic pathway analysis.
GFPT2 encodes the rate-limiting enzyme of the hexosamine biosynthesis pathway, catalyzing the conversion of fructose-6-phosphate and glutamine to glucosamine-6-phosphate. This step commits glucose flux toward UDP-GlcNAc production, the essential donor substrate for O-GlcNAcylation by O-GlcNAc transferase (OGT) and for N-linked glycan biosynthesis. GFPT2 is transcriptionally regulated by XBP1, NRF2, and HIF1A, and is activated downstream of mTORC1 in response to nutrient availability, thereby integrating metabolic cues with glycosylation capacity. Additionally, GFPT2 functionally interfaces with AMPK, a cellular energy sensor, and its product glucosamine-6-phosphate is further acetylated by glucosamine-6-phosphate acetyltransferase (GNPNAT1) to sustain downstream UDP-GlcNAc pools and global O-GlcNAcylated protein levels.
In the Raji B lymphocyte environment, GFPT2-mediated hexosamine flux modulates O-GlcNAc signaling and glycoconjugate synthesis, processes critical for B-cell receptor activity, proliferation, and stress adaptation. Disruption of GFPT2 in these polyclonal knockout cells abrogates the control of UDP-GlcNAc levels, potentially sensitizing lymphoma cells to metabolic stress and revealing vulnerabilities associated with aberrant glycosylation. This model enables dissection of how EBV oncoproteins and p53 mutation intersect with hexosamine pathway activity to drive malignant B-cell phenotypes.
Researchers can employ this knockout model to perform O-GlcNAc western blotting, flow cytometric analysis of cell surface glycans, and 13C-glutamine metabolic flux assays to quantify pathway disruption. Proliferation and apoptosis assays further define the functional consequences of GFPT2 loss, while immunoprecipitation of O-GlcNAcylated proteins facilitates identification of glycosylation-dependent signaling networks. These applications support investigations into hexosamine-dependent metabolic reprogramming in B-cell malignancies, glycobiology of immune cell function, and drug target validation for cancer metabolism. For detailed product information, validation strategies, or ordering, please contact Ascent Research.
